Real-World Evidence of Improved Patient Outcomes with Reslizumab in Adults with Severe Eosinophilic Asthma: A Subgroup Analysis of Patients Receiving Reslizumab for More Than 12 Months
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE（2020）
Key words
Asthma
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined